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Low expression of Talin1 
is associated with advanced 
pathological features in colorectal 
cancer patients
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Fahimeh Fattahi2, Elmira Gheytanchi1, Mahdi Alemrajabi6, Marzieh Ebrahimi4* & 
Zahra Madjd1,2,5*
To explore the proper prognostic markers for the likelihood of metastasis in CRC patients. Seventy-
seven fresh CRC samples were collected to evaluate the mRNA level of the selected marker using Real-
time PCR. Moreover, 648 formalin-fixed paraffin-embedded CRC tissues were gathered to evaluate 
protein expression by immunohistochemistry (IHC) on tissue microarrays. The results of Real-Time 
PCR showed that low expression of Talin1 was significantly associated with advanced TNM stage 
(p = 0.034) as well as gender (p = 0.029) in mRNA levels. Similarly, IHC results indicated that a low level 
of cytoplasmic expression of Talin1 was significantly associated with advanced TNM stage (p = 0.028) 
as well as gender (p = 0.009) in CRC patients. Moreover, decreased expression of cytoplasmic Talin1 
protein was found to be a significant predictor of worse disease-specific survival (DSS) (p = 0.011) in the 
univariate analysis. In addition, a significant difference was achieved (p = 0.039) in 5-year survival rates 
of DSS: 65% for low, 72% for moderate, and 88% for high Talin1 protein expression. Observations 
showed that lower expression of Talin1 at both the gene and protein level may drive the disparity of 
CRC patients’ outcomes via worse DSS and provide new insights into the development of progression 
indicators because of its correlation with increased tumor aggressiveness.
Colorectal cancer (CRC) is one of the frequent forms of solid tumor diagnosed in both sexes  worldwide1,2. It 
is ranked as third in incidence but second in mortality in different countries, and most of deaths are caused 
by metastasis; hence, the prevention of subsequent metastasis is the main focus of clinical  research3,4. Robust 
determinants of CRC prognosis include local involvement, lymphovascular invasion, positive surgical margin, 
regional lymph node metastasis, pre-operative elevation of CEA, and high tumor  grade5,6. Moreover, traditional 
biomarkers, colono/sigmoidoscopy, imaging techniques (magnetic resonance imaging (MRI) and computed 
tomography (CT)) play specific roles as the gold standard in colorectal screening; however, they are not satisfac-
tory  enough7. Unfortunately, the early spread of tumor cells is usually not detectable, and access to more detailed 
information related to the identification of metastasis-specific molecular markers is urgently warranted.
Histopathological analysis as a prevalent standard test is applied to assess novel molecular biomarkers through 
simultaneous analysis of hundreds of tissue samples in the clinical  setting8. The cancer patient’s blood contains 
diverse tumor-derived materials, including circulating tumor cells (CTCs), and exosomes enable the minimally 
invasive monitoring of tumor evolution over time in the  clinic9,10. It seems that achieving the molecular signature 
based on CTCs and exosomes, which is completely representative of the tumor, plays a significant role in precise 
theranostics and can be utilized in combination with clinicopathological staging. From a prognostic perspective, 
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the identification of tumor metastasis-specific molecular markers which cover cancer heterogeneity and increase 
longitudinal surveillance of patients is essential for precision  medicine11.
Although large‐scale studies have been carried out to identify novel biomarkers with great prognostic value, 
investigations of metastasis-related molecular markers should be increased to actualize the exact prediction of the 
time of metastasis. Advances in high throughput technology in omics data, especially transcriptomic approaches 
such as microarrays and RNA sequencing, would increase our knowledge of the molecular markers involved in 
CRC metastasis, resulting in the identification of potential therapeutic targets for CRC  patients12,13. To the best 
of our knowledge, just a couple of studies have investigated the direct correlation between molecular metastasis 
cascades in CTCs and exosomes. Hence in the present study, databases were screened in order to analyze the 
common expression profile of these biomarkers as an essential step in understanding the mechanism of metastasis 
and in discovering the prognostic markers for CRC 14. This study was performed using integrated analysis of bio-
informatics data related to the molecular markers involved in CRC metastasis in both CTCs and exosomes. Using 
the GEO, Exocarta, and Vesiclepedia databases, similarities in the expressed genes among the above-mentioned 
biomarkers were identified. Both gene ontology (GO) analysis and KEGG  pathway15 were examined to identify 
key candidate genes, and it was found that Talin1 could provide significant prognostic value in CRC metastasis.
The evaluation and validation of biological fluids markers as debatable matter should be assessed on tissue 
samples because of the lack of a consensus over isolation and characterization. Therefore, this step was taken in 
the current study to optimize the novel findings in the broad range of samples. The mRNA expression of Talin1 in 
fresh colorectal tumor samples and their adjacent normal tissues as the control were evaluated using Real-Time 
PCR. Then, to explore the protein localization and expression level of Talin1 in CRC samples as well as its cor-
relation with clinicopathological features and survival outcome in CRC patients, the findings from the analysis 
of gene expression data were validated and confirmed on a large series of CRC tissue microarrays (TMAs) using 
the immunohistochemistry (IHC) technique.
Results
Bioinformatics approach. To find the valuable molecular marker between CTCs and tumor-derived 
exosomes that was affected in metastasis after online analysis of the total similarity of their expressed genes, the 
following 15 genes were found: TLN1, TMEM51, GNPNAT1, RPS4X, MARCKSL1, FARP1, RHOB, HSP90AB1, 
LFNG, AHNAK, RPSA, CNPY2, PRDX1, SLC25A5, and TGFBI, as shown in Fig. 1. A detailed analysis of these 
genes was applied in online web tools such as EnrichR as a collection of databases, and the results based on a p 
value < 0.05 as the cut-off criteria are summarized in Supplementary Table 2.
After data analysis of the included genes related to CTCs and exosomes in the literature, it was proven that 
the overexpression of various integrins can promote cancer cells to be more motile and more invasive. These 
adhesion molecules can be considered as a major potential breakthrough in oncologic  treatment16,17, even as a 
regulators of cancer stemness, metastasis, and drug  resistance18. Talin because of structural and functional sig-
nificance with integrin cytoplasmic tails resulting in extracellular integrin compartments rearrangements and 
integrin  activation19. Specifically, Talin1, which functionally contributes to the extravasation and metastasis of 
colon cancer  CTCs20, was selected for the current evaluation. Talin1 protein expression was significantly local-
ized in the cytoplasm that mediates integrin interactions with the extracellular matrix (ECM). From another 
side, for cell spreading and migration, the link between ECM- bound integrins and intracellular F actin is  vital21. 
Talin1 mediates both inside-out and outside-in signaling, which leads to subsequent  cascades22,23 and also has 
a direct effect on the regulation of insulin signaling, actin dynamic, and granule  trafficking24. Talin serves as 
tension-sensing anchoring as well as a unique mechanotransductive point to link the cells to the ECM. It has 
Figure 1.  The common molecular markers between CTCs and exosome in databases. Fifteen hub genes were 
extracted from our mRNA and protein entrance mentioned databases.
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been proven using cryoelectron microscopy (cryo-EM) full-length structure examination that the function of 
Talin could be regulated as a two-way mode of auto-inhibition, and the fast switching between its inactive con-
formations and active could regulate Focal adhesion kinase (FAK)  turnover25. In our evaluation, focal adhesion 
among cellular components, cadherin, and RNA binding between molecular function were spotlighted. Also, 
cytoskeletal anchoring at plasma membrane, platelet aggregation, cell–cell adhesion, and junction throughout 
the biological process were considered significantly highlighted. Additionally, the KEGG pathway (as shown in 
Fig. 2) was common, and it was also related to cancer, like MAPK and integrin.
Overall, the major mediators of such cellular responses are integrins, which link to the actin cytoskeleton 
via Talin as a cytoskeletal  protein26. Talin1 plays a key role in malignancies through implication in cell adhesion, 
migrations, proliferation, invasion, apoptosis, cytoskeleton remodeling, anchorage-independent growth, and 
tumorigenicity. In Fig. 3, the interaction of Talin and other molecules in malignancies are shown.
Patients’ characteristics of fresh tissue samples. The current study included seventy-seven fresh tis-
sue samples from CRC patients, 52 (67.4%) of which came from males and 25 (32.6%) from females (male/
female ratio = 2.12). The median age of patients was 60 years (SD = 14.79, range 20–87); 37 (48%) patients were 
aged ≤ 60 years and 40 (52%) were aged > 60. Eight (10.4%) cases were diagnosed as stage I, 25 (32.6%) stage II, 
Figure 2.  KEGG pathway list related to the 15 excluded genes based on P-Value.
Figure 3.  Talin1 plays significant roles in cancer related pathway.
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27 (35%) and 17 (22%) stage III and IV respectively. Thirty-two (41.6%) cases were low-grade adenocarcinomas, 
and 14 (18.2%) and 31 (40.2%) were moderated and poorly differentiated adenocarcinomas, respectively.
Associations between Talin1 mRNA expression and clinicopathological parameters in fresh 
tissue samples. Talin1 is ubiquitously expressed. Websites like  Uniprot27 and  Genecards28 showed it as local-
ized within the cytosol, extracellular, and in the cytoskeleton. The expression profiles of Talin1 were decreased in 
patients with CRC compared with the healthy group (p < 0.043) according to Real-Time PCR (Fig. 4).
Pearson’s χ2 test revealed that a statistically significant association among expression levels of Talin1 mRNA 
and TNM stage (p = 0.034) as well as gender (p = 0.029), indicating an association between the low level expres-
sion of Talin1 and an increased TNM stage (Table 1).
The nonparametric Kruskal–Wallis and Mann–Whitney U tests were utilized to measure the differences 
between the median expressions of Talin1 among the groups. The results of the Mann–Whitney U test also 
showed a statistically significant difference in the median level of Talin1 mRNA expression between stages I and 
III (p = 0.015) and stages II and III (p = 0.028). Further, we did not observe any statistically significant differences 
in the median level of Talin1 mRNA expression between other stages (Fig. 5). No association was found between 
Talin1 mRNA expressions or with other clinicopathological characteristics (Table 1).
Prognostic value of Talin1 mRNA expression for clinical outcome in CRC patients. From the 
77 CRC samples, 70 (91%) patients had no history of recurrence, while 7 (9%) patients were positive. In 42 
(54.5%) metastasis occurred, while 35 (45.5%) patients were negative for it. Thirty (39.0%) patients had no 
history of metastasis, recurrence, or cancer-related death, while 47 (61.0%) patients for these parameters were 
positive. During the follow-up period, cancer-related death in 26 (33.8%) patients was reported. The mean dura-
tion of follow-up time was 20 months (SD = 11.3(, median was 25 months (8, 28), and the range was from 1 to 
33 months. The mean DSS time for patients with high and low expression of Talin1 mRNA were 23.8 (SD = 1.6) 
and 27.2 (SD = 3.4) months, respectively.
The results of the Kaplan–Meier curve demonstrated that patients with low Talin1 mRNA expression had 
shorter DSS compared to patients with high expression of Talin1 but without a statistically significant association 
(Log Rank test, p = 0.201) (Fig. 6A).
Furthermore, the mean PFS time for patients with low and high expression rates of Talin1 mRNA were 24.9 
(SD = 0.89) and 21.7 (SD = 3.2) months, respectively. The Kaplan–Meier curve showed that low level Talin1 
expression is not significantly related to PFS (p = 0.698) (Fig. 6B).
Characteristics of patients’ FFPE tissue samples. Because the application of tissue microarray (TMA) 
technology has covered the evaluation of clinical values of huge number of candidate markers, 760 cases were 
included in this research, and for final scoring, 648 CRCs tissues were left. The FFPE population samples con-
sisted of 303 (46.8%) male and 262 (40.4%) female patients, with a male/female ratio of 1.15. The median age of 
patients was calculated as 60 years (SD = 14.79, range 23–92). To clarify, 298 (46.0%) were ≤ 60 and 267 (41.2%) 
were > 60. Tumor size ranged from 1 to 20 cm, and tumors were classified into two groups. Three hundred and 
eighty-two (59.0%) of cases had tumors that were smaller in size than the mean (size ≤ 4.5) and 181 (27.9%) had 
tumors larger than the mean (size > 4.5). In this study, 90 (13.9%) patients had stage I, 254 (39.2%) stage II, 198 
(30.6%) stage III, and 22 (3.4%) stage IV tumors. Moreover, 212 (32.7%) cases were grade I, 316 (48.8%) were 
grade II, and 34 (5.2%) were grade III; VI was found in 87 (13.4%) cases, and LNI and NI were observed in 212 
(32.7%) cases. Tumor recurrence was seen in 96 (14.8%) patients, and 90 (13.9%) patients showed distant metas-
tasis during the follow-up period.
Expression of Talin1 protein in CRC and adjacent normal tissues samples. The expression level of 
Talin1 protein was evaluated using IHC on TMA sections by three scoring methods. H-score consist of staining 
intensity and percentage of positive tumor cells. In the CRC samples, Talin1 was expressed at varying intensi-
Figure 4.  The expression levels of Talin1 using Real-Time PCR in fresh tissue samples of CRC.
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ties in the cell cytoplasm and ECM. Cytoplasmic and ECM expressions of Talin1 were detected in 643 (99.2%) 
and 628 (96.9%) CRC cases, respectively. The mean expression of Talin1 was 149 in cytoplasm and 138 in ECM. 
Talin1 expression based on the H-score demonstrated that low, moderate, and high levels of cytoplasmic expres-
sion of Talin1 were observed in 205 (31.6%), 349 (53.9%), and 94 (14.5%) CRC samples, respectively. Moreover, 
low, moderate, and high ECM expression of Talin1 was found in 235 (36.3%), 379 (58.5%), and 34 (5.2%) CRC 
patients, respectively (Table 2). The expression of Talin 1 was observed in the cytoplasm and ECM in all cases of 
adjacent normal tissue (Table 2). The mean expression of Talin1 was 151 in cytoplasm and 161 in ECM; there-
fore, Talin1 expression was greater in the adjacent normal tissue samples than in CRC samples, particularly in 
ECM expression. Moreover, human kidney tissue, showed strong staining as a positive control (Fig. 7).
Associations between Expression of Talin1 protein and clinicopathological characteristics in 
CRC patients. The results of Pearson’s χ2 test showed that there is an association between expression levels 
of Talin1 and TNM stage (p = 0.028) as well as gender (p = 0.009) (Table 3). The non-parametric Kruskal–Wallis 
test indicated a difference between the median expression level of Talin1 protein and various TNM stages (I–IV) 
(p = 0.004). The results of the Mann–Whitney U test revealed a statistically significant difference in the median 
level of Talin1 protein expression between stages I and II (p = 0.013) and stages II and III (p = 0.001). We did not 
find any statistically significant differences in the median level of Talin1 protein expression between other stages 
of CRC cases (Fig. 8).
Further, the results of Spearman’s correlation exhibited a significant adverse correlation between Talin1 pro-
tein expression and advanced TNM stages (p = 0.038). No association was found between cytoplasmic Talin1 
protein expression and the other clinicopathological characteristics (Table 3).
The results of Pearson’s χ2 and Spearman’s correlation tests showed that there is no association or correlation 
between ECM Talin1 expression and the clinicopathological parameters of CRCs patients (Table 4).
Table 1.  The association between mRNA Talin1 expression and clinicopathological parameters of fresh tissue 
colorectal cancer (CRC) samples. P value; Pearson’s χ2 test.
Patients and tumor characteristics Total samples N (%)
mRNA Talin1 expression
P valueLow N (%) High N (%)
Median age, years (Range)
 ≤ Median age 37 (48) 24 (31.2) 13 (16.9)
 > Median age 40 (52) 28 (36.3) 12 (15.6) 0.379
Gender
Male 52 (67.4) 39 (50.6) 13 (16.9) 0.027
Female 25 (32.6) 24 (31.2) 1 (1.3)
(Male/Female) 2.12
Tumor differentiation
Well 32 (41.6) 29 (37.7) 3 (3.9) 0.055
Moderate 14 (18.2) 10 (13) 4 (5.2)
Poor 31 (40.2) 21 (27.2) 10 (13)
TNM stages
I 8 (10.4) 7 (9) 1 (1.3) 0.034
II 25 (32.6) 23 (29.9) 2 (2.6)
III 27 (35) 19 (24.7) 8 (10.4)
IV 17 (22) 15 (19.5) 2 (2.6)
Vascular invasion (VI)
Present 21 (27.2) 16 (20.7) 5 (6.5) 0.396
Absent 56 (72.8) 47 (61.1) 9 (11.7)
Lymph node invasion (LNI)
Involved 42 (54.5) 32 (41.6) 10 (13) 0.162
None 35 (45.5) 31 (40.2) 4 (5.2)
Neural invasion (NI)
Involved 25 (32.6) 22 (28.6) 3 (3.9) 0.347
None 52 (67.4) 41 (53.2) 11 (14.3)
Distant metastasis
Present 42 (54.5) 32 (41.6) 10 (13) 0.162
Absent 35 (45.5) 31 (40.2) 4 (5.2)
Tumor recurrence
Yes 7 (9) 7 (9) 0 (0.0) 0.221
No 70 (91) 56 (72.7) 14 (18.3)
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Prognostic value of Talin1 protein expression for clinical outcome in CRC . Out of 648 CRC sam-
ples included in the present study, survival analysis was performed on 350 patients for whom follow-up data was 
accessible. From these 350 patients, 239 (68.3%) patients had no history of metastasis, recurrence, or cancer-
related death, while 111 (31.7%) patients for these parameters were positive. In 91 (26.0%) patients metastasis 
and in 96 (27.4%) ones recurrence occurred. In 97 (27.7%), patients cancer-related death was documented dur-
ing the mean duration of 45.0 months (SD = 27.6) as follow-up time with a median of 41.0 months (27, 66); the 
range was from 1 to 117 months.
Survival outcomes based on expression of Talin1 in CRC . Kaplan–Meier curve results indicated 
significant differences between the patients with three groups of cytoplasmic expression rates of Talin1 and DSS 
(Log Rank test, p = 0.048) (Fig. 9A). The mean DSS times for patients with high, moderate, and low cytoplasmic 
expression of Talin1 were 91 (SD = 4.6), 86 (SD = 3.7), and 47 (SD = 4.0) months, respectively. Furthermore, the 
5-year survival rates for DSS in patients whose samples expressed three groups of cytoplasmic Talin1 expression 
was 88%, 72%, and 65%, respectively (p = 0.039). Besides, there was no significant differences between PFS and 
patients with cytoplasmic Talin1 expression levels (p = 0.079) (Fig. 9B). The mean PFS times for patients with 
three groups of cytoplasmic expression of Talin1 were 87 (SD = 5.1), 81 (SD = 3.9), and 74 (SD = 4.3) months, 
respectively.
Univariate and multivariate analyses were performed to investigate whether Talin1 expression was an inde-
pendent prognostic factor of DSS or PFS and to assess the clinical significance of various parameters that might 
influence survival outcomes in CRC  patients29. Among all of the clinicopathological parameters, only cytoplasmic 
Talin1 expression (p = 0.050), LNI (p = 0.010), NI (p = 0.008), distant metastasis (p < 0.001), tumor recurrence 
(p < 0.001), and age (p = 0.009) affecting DSS in univariate analysis. In addition, in multivariate analysis, only age 
(p = 0.015) was significantly related to DSS in these cases (Table 5).
Kaplan–Meier analysis showed that there were no differences between DSS or PFS and the patients with three 
groups of ECM expression of Talin1 (Log Rank test; p = 0.815, p = 0.595), respectively. Moreover, the results of 
univariate and multivariate analyses indicated that the listed clinicopathologic variables were not affecting the 
DSS or PFS of CRC patients.
Discussion
Because cross-talking between cancer cells and exosomes plays a vital role in the CRC dynamic network, espe-
cially in  metastasis30, the identification and characterization of both molecular markers as powerful tools in 
non-invasive cancer monitoring are significant steps to improving our understanding of molecular and cellular 
Figure 5.  Box plot analysis of mRNA Talin1 expression levels in stage I to IV. Based on the standard definitions, 
each box-plot shows the median (bold line) and interquartile lines (box). The result of Mann–Whitney U 
test showed that there is an association for the median of Talin1 mRNA expression between stages I and III 
(p = 0.015) as well as stages II and III (p = 0.028). There were no statistically significant differences in the median 
level of Talin1 mRNA expression between other stages.
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Figure 6.  (A) Kaplan–Meier curves for disease-specific survival (DSS) and progression-free survival (PFS) 
based on mRNA Talin1 expression levels in CRC patients. In CRC patients, lower level of Talin1 mRNA 
expression was associated with shorter DSS compared to the tumors with high expression of Talin1 mRNA 
expression (P = 0.201). (B) Kaplan–Meier curve showed that low level of Talin1 expression is not significantly 
related to PFS (P = 0.698).
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mechanisms of cancer  metastasis31. Furthermore, the identification of new prognostic markers for the likelihood 
of metastasis that can stratify patients into various classification is clearly warranted. Therefore, considering 
the heterogeneity and complexity of CRC, this study was conducted to predict prognoses of CRC patient based 
on the evaluation of their gene expression network and to the clinical significance of their common molecular 
marker by bioinformatics analysis in multiple fashions. We take advantage of the limited available data related 
to CTC and exosome collection assays throughout online web tools for tracking CRC metastasis. “Wet-lab” 
experiments using patient specimens for identifying cancer biomarkers through bioinformatics analysis were 
considered vital. The best application of that can be develop a practically manageable gene based on applying p 
values and enrichment pathway  analysis32.
Traditional biomarkers (CEA, CA19-9 and FOBT), as well as colon/sigmoidoscopy, play an unsatisfactory 
specificity role in CRC  screening7. Since the limitation of these various methods are  considerable33 shifting to 
CTCs and TDEs as a liquid biopsy  approach34,35 attracted much attention and help to discover markers which 
are important in diagnostic, prognostic and cancer  staging10,36,37, estimation of relapse risk, therapeutic targets 
 identification38,39, and proper monitoring of  patients8,40. Regardless of the metastatic site, CTC enumeration are 
enough as a proper cancer-monitoring index whenever CEA and other marker levels are not  measurable41,42.
Although several mechanisms are involved in cancer progression, recent evidence points to EMT and CSCs 
as having significant roles in these  processes43. EMT plays an important role in the invasion and metastasis of 
CRC, which is mediated by FAK. However, whether FAK participates in EMT, through the EGF/EGFR signal-
ing pathway, remains  unknown44. Talin1 can activate integrin’s as core  regulators45 and play an important role 
as a focal adhesion proteins as well as be mediators of adhesion to the  ECM46. Therefore, it must be considered 
extensively to determine its role clearly. FAK-Talin binding is required for adhesion turnover and cell motility 
and in our view has a significant point in common with molecules between circulating tumor cells (CTCs) and 
tumor-derived exosomes (TDEs).
In malignant tumors, EMT is crucial for acquisition of a mesenchymal phenotype with invasive and meta-
static properties leading to tumor progression. The important markers related to this process include Twist 47–49, 
E-cadherin, vimentin, N-cadherin, Snail, Slug, integrin’s, cytokeratin’s, fibronectin, b-catenin, ZEB1, ZEB2, and 
TGFb50,51. The correlation analysis was performed between two markers (Talin1 and Twist1) and the results 
showed that there is no significant correlation between cytoplasmic expression of them in these series of CRC 
patients (p-value = 0.104).
Additionally, Most of the fifteen genes that were obtained from our bioinformatics analysis, have been previ-
ously implicated in cancer development, but Talin1 was selected due to its most important biological roles in 
migrant cells. Assembly and disassembly of FAK including Talin are essential for cell migration; meanwhile, 
molecular mechanisms details remained poorly understood and must be  elucidated52. Up and down regulation 
of FAK protein expression might have a profound effect on signal transduction; for example, FAK expression 
levels were increased in primary CRC compared with normal mucosa and decreased in liver  metastases53. In 
addition, our findings point towards Talin1 targeting as a promise for the future, and we supposed that EMT and 
stemness have been extensively investigated in the field of CTC-related  research54. With regard to metastasis, the 
Table 2.  Cytoplasmic and extra cellular matrix (ECM) Talin1 expression (Intensity of staining, percentage 
of positive tumor cells, and H-score in FFPE colorectal cancer (CRC) and adjacent normal tissues. H-score 
indicates Histological score.
Scoring system
Cytoplasmic expression N (%) ECM expression N (%)
CRC samples Adjacent normal tissues CRC samples Adjacent normal tissues
Intensity of staining
Negative (0) 5 (0.8) 24 (35.8) 20 (3.1) 10 (14.9)
Weak (+ 1) 187 (28.9) 33 (49.3) 189 (29.2) 50 (74.6)
Moderate (+ 2) 361 (55.7) 3 (4.5) 404 (62.3) 0 (0.0)
Strong (+ 3) 95 (14.7) 0 (0.0) 35 (5.4) 0 (0.0)
Not identified 0 (0.0) 7 (10.4) 0 (0.0) 7 (10.4)
Percentage of positive tumor cells
 < 25% 18 (2.8) 0 (0.0) 30 (4.6) 0 (0.0)
25–50% 25 (3.9) 0 (0.0) 51 (7.9) 1 (1.5)
51- 75% 156 (24.1) 6 (9.0) 162 (25.0) 11 (16.4)
 > 75% 449 (69.3) 54 (80.6) 405 (62.5) 48 (71.6)
Not identified 0 (0.0) 7 (10.4) 0 (0.0) 7 (10.4)
H-score (3 groups)
0–100 205 (31.6) 25 (37.3) 235 (36.3) 11 (16.4)
101–200 349 (53.9) 32 (47.8) 379 (58.5) 49 (73.1)
201–300 94 (14.5) 3 (4.5) 34 (5.2) 0 (0.0)
Not identified 0 (0.0) 7 (10.4) 0 (0.0) 7 (10.4)
Total 648 (100) 67 (100) 648 (100) 67 (100)
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Figure 7.  Immunohistochemical (IHC) analysis of Talin1 expression in different colorectal cancer (CRC) samples. CRC samples 
expressed Talin1 at various levels. Cytoplasmic expression of Talin1 at various levels: weak (A), moderate (B), and strong (C) in 
magnification of × 200; Weak (A-1), moderate (B-1), and strong (C-1) in magnification × 400. ECM expression of Talin1 in CRC at 
various levels is as follows: weak (D), moderate (E), and strong (F) in magnification × 200. Weak (D-1), moderate (E-1), and strong (F-
1) in magnification × 400. IHC staining of kidney tissue was presented as positive (H) and negative (I) controls, adjacent normal tissue 
sample (G, G-1) in magnification × 200; and × 400.
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identification of molecular markers that robustly define a subset of CTCs which are enriched in CSCs are  vital55. 
Thus, an improved understanding of the EMT/CTC/CSC connections may uncover the novel therapeutic targets 
and underline tumorigenicity  mechanisms56.
Several studies have previously investigated levels of Talin1 expression in CRC in various areas such as by 
western blot analysis, HPLC-Chip/MS analysis, and enzyme-linked immunosorbent assay (ELISA). Neverthe-
less, no study was found that addressed the expression of Talin1 either in mRNA or protein levels in CRC tissue. 
Table 3.  The association between cytoplasmic Talin1 expression and clinicopathological parameters of 
colorectal cancer (CRC) samples (Intensity of staining and H-score). H-score indicates Histological score. 






Intensity of staining N (%) P value H-score N (%) P value
0 (Negative) 1 + (Weak) 2 + (Moderate) 3 + (Strong) H-score 0–100 H-score 101–200 H-score 201–300
Median age, years 
(Range) 60 (23–92)
 ≤ Median age 298 (46.0) 2 (50.0) 87 (50.9) 161 (51.8) 48 (60.8) 0.492 95 (51.6) 156 (51.5) 47(60.3) 0.359
 > Median age 267 (41.2) 2 (50.0) 84 (49.1) 150 (48.2) 31 (39.2) 89 (48.4) 147 (48.5) 31 (39.7)
Not identified 83 (12.8) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
Gender
Male 303 (46.8) 0 (0.0) 93 (54.4) 157 (50.5) 53 (67.1) 0.009 96 (52.2) 154 (50.8) 53 (67.9) 0.023
Female 262 (40.4) 4 (100.0) 78 (45.6) 154 (49.5) 26 (32.9) 88 (47.8) 149 (49.2) 25 (32.1)
Not identified 
(Male/Female) 83 (12.8) 1.15 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
Mean tumor size 
(cm) 4.5 (1–20)
 ≤ Mean 382 (59.0) 2 (50.0) 115 (67.6) 212 (68.2) 53 (67.9) 0.896 123 (67.2) 207 (68.3) 52 (67.5) 0.967
 > Mean 181 (27.9) 2 (50.0) 55 (32.4) 99 (31.8) 25 (32.1) 60 (32.8) 96 (31.7) 25 (32.5)
Not identified 85 (13.1) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
Tumor differentiation
Well 212 (32.7) 1 (25.0) 66 (38.8) 113 (36.5) 32 (41.0) 0.832 68 (37.2) 112 (37.1) 32 (41.6)
Moderate 316 (48.8) 3 (75.0) 91 (53.5) 179 (57.7) 43 (55.1) 102 (55.7) 172 (57.0) 42 (54.5) 0.852
Poor 34 (5.2) 0 (0.0) 13 (7.6) 18 (5.8) 3 (3.8) 13 (7.1) 18 (6.0) 3 (3.9)
Not identified 86 (13.3) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
TNM stages
I 90 (13.9) 1 (25.0) 32 (18.7) 46 (14.8) 11 (14.1) 0.254 35 (19.0) 44 (14.5) 11 (14.3)
II 254 (39.2) 1 (25.0) 66 (38.6) 143 (46.0) 44 (56.4) 68 (37.0) 142 (46.9) 44 (57.1) 0.028
III 198 (30.6) 2 (50.0) 68 (39.8) 106 (34.1) 22 (28.2) 76 (41.3) 101 (33.3) 21 (27.3)
IV 22 (3.4) 0 (0.0) 5 (2.9) 22 (28.2) 1 (1.3) 5 (2.7) 16 (5.3) 1 (1.3)
Not identified 84 (13.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
Vascular invasion (VI)
Present 87 (13.4) 1 (25.0) 24 (14.0) 49 (15.8) 13 (16.7) 0.884 28 (15.2) 47 (15.5) 12 (15.6) 0.995
Absent 477 (73.6) 3 (75.0) 147 (86.0) 262 (84.2) 65 (83.3) 156 (84.8) 256 (84.5) 65 (84.4)
Not identified 84 (13.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
Lymph node invasion (LNI)
Involved 212 (32.7) 2 (50.0) 71 (41.5) 114 (36.7) 25 (32.1) 0.471 79 (42.9) 109 (36.0) 24 (31.2) 0.14
None 352 (54.3) 2 (50.0) 100 (58.5) 197 (63.3) 53 (67.9) 105 (57.1) 194 (64.0) 53 (68.8)
Not identified 84 (13.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
Neural invasion (NI)
Involved 212 (32.7) 1 (25.0) 33 (19.3) 71 (22.8) 10 (12.8) 0.254 36 (19.6) 70 (23.1) 9 (11.7) 0.08
None 352 (54.3) 3 (75.0) 138 (80.7) 240 (77.2) 68 (87.2) 148 (80.4) 233 (76.9) 68 (88.3)
Not identified 84 (13.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
Distant metastasis
Present 90 (13.9) 2 (40.0) 30 (28.0) 48 (26.2) 10 (18.5) 0.509 35 (29.2) 46 (26.1) 9 (17.0) 0.238
Absent 259 (40.0) 3 (60.0) 77 (72.0) 135 (73.8) 44 (81.5) 85 (70.8) 130 (73.9) 44 (83.0)
Not identified 299 (46.1) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
Tumor recurrence
Yes 96 (14.8) 2 (40.0) 28 (26.2) 55 (30.1) 11 (20.0) 0.45 33 (27.5) 53 (30.1) 10 (18.5) 0.248
No 254 (39.2) 3 (60.0) 79 (73.8) 128 (69.9) 44 (80.0) 87 (72.5) 123 (69.9) 44 (81.5)
Not identified 298 (46.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
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Hence, due to the existence of information gaps regarding the expression of Talin1 in both mRNA and protein 
levels, the present study was designed to examine that in a well-characterized series of 77 fresh and 648 FFEP 
CRC tissue samples. This is also the first report of localization of Talin1 expression in cytoplasm and ECM in 
a large number of tumor samples with evaluation of its impact on CRC prognosis. The current results showed 
that low level mRNA expression of Talin1 is associated with increases in TNM stages. Furthermore, the results 
of TMA revealed an adverse association between the cytoplasmic expression levels of Talin1 and increasing 
TNM stage and gender, while no association between the ECM expression of Talin1 and the clinicopathological 
parameters was found. It was determined that the localization of Talin expression depends completely upon its 
function related to integrins. Moreover, a statistically significant difference was observed in the median level of 
Talin1 mRNA and protein expression between different stages. To clarify, the comparison of low stages (I–II) and 
high stages (III) showed that Talin1 mRNA and protein cytoplasmic expression levels are associated with CRC 
aggressiveness. It is noteworthy that the continuous refinement of the TNM system, T (tumor), N (node), and 
M (metastasis) staging define the prognosis and patient outcome and play a pivotal role in decision-making for 
 treatment57,58. Accumulating data underlines the importance of structuring the management of CRC patient’s 
survival by stages at diagnosis and prognostic  stratification59,60. In addition, LNI, NI, distant metastasis, tumor 
recurrence, and age were prognostic variables in univariate analysis that depicted the associations between these 
parameters and more aggressive tumor behavior. In cytoplasmic Talin1 expression, only age was a prognosis 
factor affecting the DSS in multivariate analysis. It was previously shown that age and comorbidities worsened 
the survival rate of CRC  patients61. In this study, the results exhibited that low level cytoplasmic expression of 
Talin1 compared with ECM expression is related to the degree of malignancy and progression in CRC cases. 
Talin1 cytoplasmic expression can be considered more significant in comparison with ECM  ones62,63.
Previous articles have shown that there are many challengeable reports regarding Talin1 expression, analysis, 
and localization in various tissues. The first study related to Talin expression showed that it  increased64, but eight 
years later the reduced expression of Talin in liver metastases compared with matched primary human CRC 
was  reported65. Barbazan et al. introduced one molecular pattern in CRC for CTC  detection66,67. Their research 
was continued by Insua et al., who included Talin1 as a gene involved in CTC extravasation during metastatic 
Figure 8.  Box plot analysis of Talin1 expression levels in stage I to IV. Based on the standard definitions, each 
box-plot shows the median (bold line) and interquartile lines (box). The result of Mann–Whitney U test showed 
that there is a statistically significant association for the median of cytoplasmic Talin1 expression between stages 
I and II (P = 0.013) as well as stages II and III (P = 0.001). There were no statistically significant differences in the 
median level of Talin1 protein expression between other stages.
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dissemination in their gene expression panel, which was composed of GAPDH, VIL1, CLU, TIMP1, TLN1, 
LOXL3, and ZEB2. This panel was checked as a prognostic and predictive tool in metastatic CRC blood samples. 
Patients with higher gene panel expression compared with low ones had reduced PFS and OS rates (p = 0.003 
and p = 0.001),  respectively65. According to the current results, this prognostic value seems to be related to Talin1 
expression accompanied by the other markers, which were important in the  panel53. One recent study revealed 
that Talin1 expression was upregulated in CRC, and the proliferation, migration, and invasive ability of the CRC 
Table 4.  The association between extra cellular matrix (ECM) Talin1 expression and clinicopathological 
parameters of colorectal cancer (CRC) samples (Intensity of staining and H-score). H-score indicates 






Intensity of staining N (%)
P value
H-score N (%)
P value0 (Negative) 1 + (Weak) 2 + (Moderate) 3 + (Strong) H-score 0–100 H-score 101–200 H-score 201–300
Median age, years 
(Range) 60 (23–92)
 ≤ Median age 298 (46.0) 14 (73.7) 82 (49.1) 187 (54.0) 15 (45.5) 0.160 109 (52.9) 174 (53.2) 15 (46.9) 0.789
 > Median age 267 (41.2) 5 (26.3) 85 (50.9) 159 (46.0) 18 (54.5) 97 (47.1) 153 (46.8) 17 (53.1)
Not identified 83 (12.8) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
Gender
Male 303 (46.8) 6 (31.6) 82 (49.1) 195 (56.4) 20 (60.6) 0.79 99 (48.1) 185 (56.6) 19 (59.4) 0.126
Female 262 (40.4) 23 (68.4) 85 (50.9) 151 (43.6) 13 (39.4) 107 (51.9) 142 (43.4) 13 (40.6)
Not identified 
(Male/Female) 83 (12.8) 1.15 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
Mean tumor size 
(cm) 4.5 (1–20)
 ≤ Mean 382 (59.0) 11 (57.9) 118 (70.7) 231 (67.2) 22 (66.7) 0.667 141 (68.4) 220 (67.7) 21 (65.6) 0.947
 > Mean 181 (27.9) 8 (42.1) 49 (29.3) 113 (32.8) 11 (33.3) 65 (31.6) 105 (32.3) 11 (34.4)
Not identified 85 (13.1) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
Tumor differentiation
Well 212 (32.7) 6 (31.6) 64 (38.3) 128 (37.3) 14 (42.4) 0.952 81 (39.3) 117 (36.1) 14 (43.8)
Moderate 316 (48.8) 12 (63.2) 91 (54.5) 195 (56.9) 18 (54.5) 112 (54.4) 187 (57.7) 17 (53.1) 0.833
Poor 34 (5.2) 1 (5.3) 12 (7.2) 20 (5.8) 1 (3.0) 13 (6.3) 20 (6.2) 1 (3.1)
Not identified 86 (13.3) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
TNM stages
I 90 (13.9) 0 (0.0) 35 (21.0) 49 (14.2) 6 (18.2) 0.199 38 (18.4) 46 (14.1) 6 (18.8)
II 254 (39.2) 10 (52.6) 69 (41.3) 159 (46.1) 16 (48.5) 88 (42.7) 151 (46.3) 15 (46.9) 0.252
III 198 (30.6) 7 (36.8) 54 (32.3) 127 (36.8) 10 (30.3) 67 (32.5) 121 (37.1) 10 (31.3)
IV 22 (3.4) 2 (10.5) 9 (5.4) 10 (2.9) 1 (3.0) 13 (6.3) 8 (2.5) 1 (3.1)
Not identified 84 (13.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
Vascular invasion (VI)
Present 87 (13.4) 3 (15.8) 25 (15.0) 56 (16.2) 3 (9.1) 0.749 32 (15.5) 52 (16.0) 3 (9.4) 0.616
Absent 477 (73.6) 16 (84.2) 142 (85.0) 289 (83.8) 30 (90.9) 174 (84.5) 274 (84.0) 29 (90.6)
Not identified 84 (13.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
Lymph node invasion (LNI)
Involved 212 (32.7) 11 (57.9) 60 (35.9) 130 (37.7) 11 (33.3) 0.285 79 (38.3) 122 (37.4) 11 (34.4) 0.907
None 352 (54.3) 8 (42.1) 107 (64.1) 215 (62.3) 22 (66.7) 127 (61.7) 204 (62.6) 21 (65.6)
Not identified 84 (13.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
Neural invasion (NI)
Involved 212 (32.7) 5 (26.3) 32 (19.2) 76 (22.0) 2 (6.1) 0.15 42 (20.4) 71 (21.8) 2 (6.3) 0.115
None 352 (54.3) 14 (73.7) 135 (80.8) 269 (78.0) 31 (93.9) 164 (79.6) 255 (78.2) 30 (93.8)
Not identified 84 (13.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
Distant metastasis
Present 90 (13.9) 5 (35.7) 29 (26.9) 54 (26.0) 2 (10.5) 0.376 37 (26.8) 51 (26.6) 2 (10.5) 0.294
Absent 259 (40.0) 9 (64.3) 79 (73.1) 154 (74.0) 17 (89.5) 101 (73.2) 141 (73.4) 17 (89.5)
Not identified 299 (46.1) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
Tumor recurrence
Yes 96 (14.8) 5 (35.7) 31 (28.7) 53 (25.5) 7 (35.0) 0.672 39 (28.3) 50 (26.0) 7 (35.0) 0.667
No 254 (39.2) 9 (64.3) 77 (71.3) 155 (74.5) 13 (65.0) 99 (71.7) 142 (74.0) 13 (65.0)
Not identified 298 (46.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
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cell line was significantly reduced by its knockdown compared with the control. In the current study, however, 
it was downregulated in advanced tumor  progression68. Analysis of Talin1 using ELISA showed no significant 
correlation between its preoperative levels in the serum of patients and age and gender; however, a significant 
correlation between Talin1 levels and tumor grade, TNM stage, and lymph node metastasis was  found69.
Figure 9.  Kaplan–Meier curves for disease-specific survival (DSS) and progression-free survival (PFS) based 
on cytoplasmic Talin1 protein expression level in CRC patients. (A) In CRC patients, lower level of Talin1 
protein expression was associated with shorter DSS compared to the tumors with high expression of this protein 
(P = 0.048). (B) Kaplan–Meier survival analysis showed that low levels of Talin1 protein expression are not 
significantly related to PFS (P = 0.079).
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The results of the Kaplan–Meier curve on protein determined that tumors with low-level expression of the 
Talin1 protein tend to have a worse prognosis for DSS. Moreover, CRC patients who expressed a lower level of 
cytoplasmic Talin1 had a worse 5-year survival rate for DSS compared with those with high expression. Thus, 
low expression level of Talin1 can be considered a worse prognostic factor of DSS in CRC patients. Talin1 levels 
could not be used as an independent prognostic factor of DSS. More prolonged follow-up time may increase 
the prognostic value of Talin1. In mRNA expression, the current finding showed that patients with low Talin1 
mRNA expression had shorter DSS compared to patients with high expression of Talin1, but the difference was 
not statistically significant. This might be due to the limited sample size and shorter follow-up period in com-
parison with FFEP samples, because all fresh tissue samples were collected on 2017.
The current study was similar to other studies conducted on Talin1 in some malignancies in its importance 
in cancer development, invasion, migration, and metastasis, and even introduces it as a cancer stem cell (CSCs) 
marker, because in the current study, Talin1 was a common marker between CTCs and  exosomes68,70–72. There-
fore, it must be mentioned that Talin1 can be an extremely helpful factor for a worse prognosis of DSS in CRC 
patients. Moreover, the use of IHC can verify the Real-Time PCR results and establish Talin1 status in routine 
clinical practice.
Conclusion
The current study is the first to exhibit that low level Talin1 mRNA expression is associated with more aggressive 
tumor behavior in CRC patients. Furthermore, we found that decreased cytoplasmic expression of Talin1 rather 
than its ECM expression has a clinical significance in CRC cases and is associated with increased invasiveness 
and poor prognosis risk for DSS in univariate analysis. To sum up, investigation of the expression pattern of 
Talin1 in the cytoplasm of tumor biopsies as a predictor and prognostic indicator of cancer progression in CRC 
patients’ tumor biopsies is useful. Extending the follow-up time might increase the prognostic value of Talin1 as 
an independent prognostic factor, but that must be confirmed in further studies.
Methods
Data set collection. To find the common molecular marker between CTCs and exosomes, first, GSE31023 
gene expression and CTC profiling by array were obtained from the NCBI GEO database (https ://www.ncbi.
nlm.nih.gov/geo) based on the GPL13497 (Agilent-026652 Whole Human Genome Microarray 4 × 44  K v2) 
platforms, containing the CTC in CRC patients (n = 6) and healthy subjects (n = 3). The GEO2R online analysis 
tool to detect the DEGs was applied, using a p value < 0.05 and |logFC|≥ 2 as cut-off criteria.
Secondly, the exosome markers were sought in two known exosome-related websites, https ://www.exoca 
rta.org and https ://micro vesic les.org, which were sequentially searched. A search for CRC cells in Vesiclepedia 
revealed 37 research sets containing 22,375 proteins and 10,813 mRNA. After duplicates were removed, a total of 
6150 proteins and 10,813 mRNA were determined. Another 1617 related CRC exosome proteins were extracted 
from Exocarta, and all of them are summarized in Supplementary Table 1.
Molecular markers are valuable tools in the development of cancer screening and monitoring strategies. GO 
and GSEA are the common useful methods employed in this study to suggest new markers among the CTCs and 
exosomes in CRC samples. GO is useful for annotating genes and identifying characteristic biological attributes 
for high-throughput data  analysis73. The GO project describe the attributes of gene products in the molecu-
lar functions, biology processes, and cellular  components74. Gene set enrichment analysis (GSEA) determines 
whether a prior defined set of genes shows statistical  significance75,76. Thus, the initially extracted markers in 
this article were subjected to STRING (https ://strin g-db.org/) and EnrichR (amp.pharm.mssm.edu/Enrichr/) to 
obtain a better comprehensive of the significantly related pathway, which is described in Supplementary Table 2.
Patients’ characteristics and tissue collection. In the current study, 77 CRC fresh tumor tissues and 
their adjacent normal tissue samples from 2018 to 2019 were collected from university-based hospitals (Firooz-
gar and Bahman) in Tehran, Iran. Patients who had undergone surgery without receiving any relevant chemo-
Table 5.  Univariate and multivariate Cox regression analyses of potential prognostic factor for disease-specific 
survival (DSS) in patients with colorectal cancer. H-score indicates Histological score. Values in bold are 
statistically significant. The variables with P value less than 0.05 were included in multivariable analyses. HR 
hazard ratio, CI confidence interval.
Covariate
Univariate analysis Multivariate analysis
HR (95% CI) P value HR (95% CI) P value
H-score 0.050 0.174
High versus Low 0.814 (0.532–1.245) 0.342 0.909 (0.582–1.418) 0.673
High versus Moderate 0.378 (0.169–0.847) 0.018 0.437 (0.183–1.042) 0.062
Age 1.780 (1.155–2.743) 0.009 1.717 (1.113–2.649) 0.015
Lymph node invasion (LNI) 0.571 (0.372–0.877) 0.010 – –
Neural invasion (NI) 0.523 (0.324–0.845) 0.008 – –
Distant metastasis 0.104 (0.066–0.162)  < 0.001 – –
Tumor recurrence 0.131 (0.084–0.203)  < 0.001 – –
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therapy or radiotherapy were included in this study. The specimens were embedded in RNA later solution, trans-
ferred to the laboratory, and frozen in liquid nitrogen. Patient information including gender, age, TNM stage, 
tumor differentiation, and distant metastasis was also recorded. To evaluate the protein expression of Talin1, 
760 FFPE tissues of CRC taken from 2010 to 2019 were collected from university-based hospitals (Firoozgar, 
Bahman, Rasool, and Hasheminejad) in Tehran, Iran. Hematoxylin and eosin (H&E) stained slides and archived 
medical records were retrieved to obtain patients’ clinicopathological characteristics, including age, gender, 
tumor size (maximum tumor diameter), tumor differentiation, TNM stage, venous invasion (VI), lymph node 
invasion (LNI), neural invasion (NI), distant metastasis, and tumor recurrence. In addition, 60 adjacent normal 
tissue samples were used to compare expression levels of the Talin1 markers in a range of tissue samples. From 
the date of surgery to the date of death was measured as Disease-specific survival (DSS). The interval between 
the primary surgery and the last follow-up visit was considered as Progression-free survival (PFS) if the patient 
showed no evidence of disease, metastasis, recurrence, CRC or disease-related death.
RNA isolation, reverse transcription, and real-time PCR. Briefly, tissue specimens were lysed and 
homogenized in the presence of a highly denaturing guanidine-thiocyanate-containing buffer that inactivates 
RNases. Trizol reagent (Sigma, USA) added to provide appropriate binding conditions were grounded. Then, the 
total RNA was isolated based on the RNAeasy Mini Kit (Qiagen Cat No. /ID: 74,104) protocol. One μg of RNA 
was reverse transcripted with PrimeScript 1st Strand complementary DNA Synthesis kit (Takara). Real-time 
PCR assay was performed on the Qiagen Rotor Gen Q system using the SYBR green Premix Dimer Eraser kit 
(TaKaRa cat number: RR820Q). The cycling conditions were an initial 30 s denaturation at 95 °C and 40 cycles 
(5 s at 95 °C, 30 s at 60 °C, and 45 s at 72 °C). The GAPDH gene was set as internal control; Talin1 expression level 
was detected in forty pairs of CRC and adjacent normal tissue samples. The primer sequences were as follows: 
GAPDH: 5′-AAC TTT GGC ATT GTG GAA GG-3′ F and 5′-CAC ATT GGG GGT AGG AAC AC-3′ R. Talin1: 5′-.
TTG GAG ATG CCA GCA AGC GACT-3′ F and 5′-CCA GTT CTG TGG CTG CCT GATT-3′. The expression levels 
of Talin1 mRNA were normalized against GAPDH levels based on the  2−ΔΔCt  approach77.
Construction of tissue microarrays (TMAs). Colorectal tissue TMAs were prepared as described 
 previously78. Briefly, our pathologist (Z.S.) examined the H&E slides to select the representative tumor area in 
each block. Then, using a precision arraying instrument (Tissue Arrayer Minicore; ALPHELYS, Plaisir, France), 
selected spots were punched into recipient blocks, and TMA blocks were constructed in three copies. In each 
TMA block, adjacent normal tissue samples were also included to compare the expression pattern of Talin1 with 
tumor tissue  specimens79,80. Due to technical problems and an insufficient amount of tissue for scoring, some 
cases were lost during the staining and excluded from the study. Tumor heterogeneity is a major concern dur-
ing the TMA procedure, and thus, at least two or three cores were evaluated from each sample to achieve better 
 results81,82.
Immunohistochemistry (IHC) staining. The protein expression of Talin1 was evaluated using our IHC 
laboratory protocol  y29,83. Sequential TMA sections at 60 °C for 30 min were dewaxed, in xylenes rehydrated, 
and then under ethanol treatment graded. 3%  H2O2 (endogenous peroxidase) were applied as blocker for 20 min 
at room temperature. Antigen was retrieved by autoclaving tissue sections for 10 min in sodium citrate buffer 
(pH 6.0). Then, all of the slides were blocked (blocker protein, Dako, Denmark) for 20 min. After serial dilution, 
1:1000 for anti-Talin1 antibody was prepared as an optimal dilution for subsequent use. The tissue sections were 
incubated overnight at 4 °C with the following antibody dilutions: anti Talin1 antibody (ab71333; Abcam, UK). 
The next day, after three washes in Tris-buffered saline (TBS), sections were incubated with anti-rabbit/anti-
mouse envision IgG–HRPO (EnVision, Dako) as the secondary antibody for 1 h. 3,3′-diaminobenzidine (DAB) 
(Dako) substrate as a chromogen for treating the TMA slides were used in 3 min at room temperature. Sections 
were counterstained with hematoxylin (Dako), in alcohol dehydrated, with xylenes cleared and mounted. TBS 
was replaced for negative controls, and only the secondary antibody was used. Meanwhile, human kidney tissue 
was used as a positive control for Talin1 staining.
Evaluation of immunostaining. Our pathologist (Z.S.) using a semi-quantitative scoring examined the 
immunostained tissue arrays system in a coded manner. Consensus was achieved by the second investigator 
(Z.M.) in difficult cases for confirming the scoring.
Scoring system. In the CRC samples, the Talin1 marker was expressed at various intensities in the cell 
cytoplasm and ECM, each of which was analyzed separately. The intensities of Talin1 staining were scored on a 
4-point scale, ranging from negative to strong (zero = negative, one = weak, two = moderate, and three = strong). 
The percentages of positive tumor cells varied between zero and 100. Histochemical score (H-score) as an overall 
score was achieved by multiplying the intensity of staining by the percentage of positive cells; then, a final score 
of 0 to 300 was given to each core. In the current study, the mean H-scores were classified into three groups: 1. 
low expression (0–100), 2. moderate expression (101–200), and 3. high expression (201–300).
Statistical analysis. SPSS software version 22.0 (IBM Corp, USA) was utilized to analyze the data. Categor-
ical data was reported by N (percentage) and quantitative data as mean (SD) and median (Q1, Q3). Pearson’s χ2 
and Spearman’s correlation tests were used to analyze the significance of associations and correlations between 
Talin1 expression and clinicopathological parameters. Kruskal–Wallis and Mann–Whitney U tests were applied 
for pairwise comparisons between groups. DSS and PFS curves were drawn using the Kaplan–Meier method, 
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and the log-rank test was used to compare the estimated curves between groups with 95% confidence intervals 
(CI). To clarify that which variables affected DSS or PFS, the Cox proportional hazards regression model was 
applied. In all parts, a p-value of < 0.05 was considered statistically significant. As noted, in the first step, all quan-
tified data was replicated an average of three times.
Ethical approval. The Research Ethics Committee of Iran University of Medical Sciences issued IR.IUMS.
REC 1395.9221513203 for this study. All procedures, including obtaining informed consent from each human 
participant before surgery, were in accordance with the above-mentioned ethical standards.
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